X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (119) 119
index medicus (109) 109
female (99) 99
male (97) 97
oncology (95) 95
middle aged (82) 82
adult (73) 73
aged (72) 72
article (53) 53
aged, 80 and over (47) 47
radiotherapy (37) 37
cancer (34) 34
prognosis (30) 30
lung neoplasms - genetics (28) 28
retrospective studies (28) 28
surgery (28) 28
chemotherapy (27) 27
survival (26) 26
treatment outcome (26) 26
carcinoma, non-small-cell lung - drug therapy (23) 23
carcinoma, non-small-cell lung - genetics (23) 23
care and treatment (23) 23
hematology, oncology and palliative medicine (23) 23
lung neoplasms - drug therapy (23) 23
lung neoplasms - pathology (23) 23
neoplasm staging (23) 23
survival rate (23) 23
adolescent (22) 22
mutation (22) 22
radiation (22) 22
radiology, nuclear medicine & medical imaging (22) 22
young adult (22) 22
abridged index medicus (20) 20
follow-up studies (18) 18
lung neoplasms - mortality (18) 18
receptor, epidermal growth factor - genetics (17) 17
research (17) 17
respiratory system (17) 17
risk factors (17) 17
survival analysis (17) 17
adenocarcinoma (16) 16
child, preschool (16) 16
therapy (16) 16
time factors (16) 16
analysis (15) 15
carcinoma, non-small-cell lung - pathology (15) 15
radiation-therapy (15) 15
child (14) 14
kaplan-meier estimate (14) 14
patient outcomes (14) 14
prospective studies (14) 14
animals (13) 13
carcinoma, non-small-cell lung - mortality (13) 13
combined modality therapy (13) 13
lung cancer (13) 13
mesothelioma (13) 13
tumors (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
erlotinib hydrochloride (12) 12
patients (12) 12
protein kinase inhibitors - therapeutic use (12) 12
transplantation (12) 12
adenocarcinoma - genetics (11) 11
diagnosis (11) 11
genotype (11) 11
lung cancer, non-small cell (11) 11
protons - therapeutic use (11) 11
alk (10) 10
antineoplastic agents - therapeutic use (10) 10
cell line, tumor (10) 10
cell lung-cancer (10) 10
disease-free survival (10) 10
growth-factor-receptor (10) 10
hematology (10) 10
mesothelioma - pathology (10) 10
non-small cell lung cancer (10) 10
pleural neoplasms - pathology (10) 10
quinazolines - therapeutic use (10) 10
radiology (10) 10
radiology and nuclear medicine (10) 10
resistance (10) 10
adenocarcinoma - pathology (9) 9
crizotinib (9) 9
erlotinib (9) 9
gefitinib (9) 9
health aspects (9) 9
immunology (9) 9
infant (9) 9
medical research (9) 9
mesothelioma - mortality (9) 9
mice (9) 9
pediatrics (9) 9
phase-ii (9) 9
pleural neoplasms - mortality (9) 9
proton therapy - adverse effects (9) 9
pulmonary and respiratory medicine (9) 9
radiotherapy dosage (9) 9
carcinoma, non-small-cell lung - metabolism (8) 8
children (8) 8
egfr (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 11, pp. 1004 - 1012
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2009, Volume 15, Issue 16, pp. 5216 - 5223
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2009, Volume 27, Issue 26, pp. 4247 - 4253
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 11/2009, Volume 106, Issue 46, pp. 19503 - 19508
Non-small cell lung cancers with activating mutations in the epidermal growth factor receptor (EGFR) are highly responsive to EGFR tyrosine kinase inhibitors... 
B lymphocytes | Cell death | Cell lines | Breast cancer | Down regulation | Genetic mutation | Apoptosis | Lung neoplasms | Cancer | Tumors | Mcl-1 | MEK | AKT | Acquired resistance | BIM | GEFITINIB | GROWTH-FACTOR-RECEPTOR | MULTIDISCIPLINARY SCIENCES | ACQUIRED-RESISTANCE | ANTITUMOR-ACTIVITY | PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET | acquired resistance | CELL LUNG-CANCER | TYROSINE KINASE INHIBITORS | PATHWAY | T790M MUTATIONS | RAPAMYCIN INHIBITOR | Erlotinib Hydrochloride | Protein Kinases - metabolism | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Receptor, ErbB-2 - genetics | Humans | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Quinolines - pharmacology | Female | MAP Kinase Kinase Kinases - antagonists & inhibitors | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Antineoplastic Combined Chemotherapy Protocols | Imidazoles - pharmacology | Breast Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Animals | Breast Neoplasms - genetics | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Mice | TOR Serine-Threonine Kinases | Carcinoma, Non-Small-Cell Lung - drug therapy | Quinazolines - pharmacology | Physiological aspects | Research | Lung cancer, Non-small cell | Phosphotransferases | Health aspects | Biological Sciences
Journal Article
Journal Article
Journal of Surgical Oncology, ISSN 0022-4790, 08/2014, Volume 110, Issue 2, pp. 115 - 122
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2008, Volume 14, Issue 21, pp. 7060 - 7067
Journal Article
Modern Pathology, ISSN 0893-3952, 11/2012, Volume 25, Issue 11, pp. 1462 - 1472
Chromosomal rearrangements leading to constitutive activation of anaplastic lymphoma receptor tyrosine kinase (ALK) define a category of lung adenocarcinomas... 
ALK | signet ring cells | hepatoid cells | small biopsy | cytopathology | lung adenocarcinoma | MICROPAPILLARY PATTERN | EML4-ALK FUSION GENE | PATHOLOGY | CANCER | EGFR | ANAPLASTIC LYMPHOMA KINASE | PROGNOSTIC-SIGNIFICANCE | MUTATIONS | INHIBITOR | Lung Neoplasms - drug therapy | Multivariate Analysis | Predictive Value of Tests | Pyrazoles - therapeutic use | Prognosis | Adenocarcinoma of Lung | Humans | Middle Aged | Adenocarcinoma, Papillary - genetics | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Carcinoma, Signet Ring Cell - genetics | Patient Selection | Young Adult | Anaplastic Lymphoma Kinase | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Adenocarcinoma - genetics | Precision Medicine | Pyridines - therapeutic use | Crizotinib | Lung Neoplasms - genetics | Adenocarcinoma, Papillary - secondary | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Adenocarcinoma - enzymology | In Situ Hybridization, Fluorescence | Logistic Models | Carcinoma, Signet Ring Cell - enzymology | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Phenotype | Adenocarcinoma, Papillary - enzymology | Carcinoma, Signet Ring Cell - secondary | Receptor Protein-Tyrosine Kinases - genetics | Biopsy | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Aged
Journal Article